SART cohort: Surgical Approach for Retrorectal Tumors Cohort
Study Details
Study Description
Brief Summary
Aim of the study :
To evaluate postoperative outcomes of all surgical approach for retrorectal tumors.
Methods :
From 2005 to 2020, all consecutive patients who underwent surgery for a retrorectal tumor in two referral tertiary center were prospectively collected.
Considering our exlusion criterias, data from XX patients were analyzed. The cohort was separated into 2 groups according to tumor localization regarding the third sacral vertebra.
Short and longterm outcomes were compared between the two groups.
Primary outcome :
90 days postoperative morbidity rate
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Retro-rectal tumors are a group of heterogeneous and rare lesions. The actual incidence has been estimated to be approximately one case per 40,000 admissions. It is most often a benign tumor that affects young women and the origin is congenital in 60% of cases. The most common benign lesion is a tailgut cyst. Chordoma is the most common malignant lesion. They are mostly asymptomatic or pauci-symptomatic. This is why their diagnosis is regularly accidentaly after a morphological examination such as an abdominal ultrasound or a CT scan. MRI is the gold standard for determining the structure of the lesion, its origin, its topography, its extension in relation to adjacent organs, parameters that are essential to define the type of surgery and its approach.
When a retro-rectal tumor is diagnosed, the standard treatment is surgical resection. A biopsy is not helpful if there is no suspicion of a degenerate lesion. Usually, lesions located under the third sacral vertebra (S3) are approached by dorsal transsacrococcygeal, perineal or combined approach (abdominal and perineal approach) while those located above S3 the approach is abdominal (laparotomy or laparoscopy). As these lesions are, in the majority of cases, benign, the functional impact of surgery is essential. Based on our experience in minimally invasive surgery and in particular in retro-rectal tumors, laparoscopy has become our first-line approach regardless of the location of the lesion compared to S3. Our hypothesis is that the minimally invasive approach is reliable, safe and allows satisfactory histological results to be obtained while limiting postoperative pain and functional sequelae.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Above S3 Lesion located above the third sacral vertebra |
Procedure: Resection of the retrorectal tumor
Surgical resection of the retrorectal mass
|
| Below S3 Lesion located below the third sacral vertebra |
Procedure: Resection of the retrorectal tumor
Surgical resection of the retrorectal mass
|
Outcome Measures
Primary Outcome Measures
- Postoperative morbidity rate [90 days]
Postoperative morbidity according to Clavien Dindo
Secondary Outcome Measures
- Mortality rate [90 days]
Mortality rate
- Reoperation rate [90 days]
Any reoperation linked to surgical resection of the retrorectal tumor
- Quality of surgical resection [90 days]
Evaluation of surgical margins according to pathological examination
- Conversion to open approach [90 days]
Conversion to laparotomy in case of mini-invasive approach
- Rate of functional outcomes [90 days]
Evaluation of fecal
- Rate of functional outcomes [90 days]
Evaluation urinary functions
- Functional outcomes [90 days]
Evaluation of sexual functions
Eligibility Criteria
Criteria
Inclusion criteria:
-
Patient presenting a retrorectal tumor
-
Surgical procedure between 01/01/2005 and 31/12/2020
Exclusion criteria:
-
age < 18 years old
-
Patients presenting a rectal tumor
-
Patients presenting a rectal duplication
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Uhmontpellier | Montpellier | France | 34295 |
Sponsors and Collaborators
- University Hospital, Montpellier
- Université Montpellier
- Centre Hospitalier Universitaire de Nīmes
Investigators
- Study Director: Thomas Bardol, University Hospital, Montpellier
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RECHMPL21_0093